Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety of Apatinib compared with second-line treatment in advanced GIST patients with first-line TKI failure. The main questions it aims to answer are: * To explore the efficacy and safety of Apatinib compared with standard second-line treatment for GIST with advanced first-line TKI failure. * To explore the expression level and MVD value of VEGFR2 in GIST, and to explore the relationship between the expression level and the location, size, mitotic image and recurrence risk grading of GIST. Patients with advanced GIST were randomly included in the trial group and the control group at a ratio of 1:1.

NCT Number	NCT05751733
Lead Sponsor	Xiangya Hospital of Central South University Collaborators: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Gastrointestinal Stromal Tumors
Enrollment	258 participants
Start Date	2023-02-01
Primary Completion	2026-01-01 (estimated)
Study Completion	2027-01-01 (estimated)
Updated on ClinicalTrials.gov	2023-03-02